Adam Brufsky
Adam Brufsky

Associate chief, Division of Hematology/Oncology

Co-director, Comprehensive Breast Cancer Center

Associate director, Clinical Investigation

University of Pittsburgh Medical Center

Latest Stories

ClinicalFreeTrials & Tribulations
In my twenty-two years of practicing medicine, I have observed the evolution of genomic testing and its increasing utility in oncology. With the growing interest in precision medicine for breast cancer patients, I have found it important to decipher the differences between the two most clinically validated genomic tests, MammaPrint and Oncotype DX, and their phase III trials, MINDACT and TAILORx, respectively. To that end, now that some time has passed since the presentation of the TAILORx findings at the American Society for Clinical Oncology Annual Meeting, I'd like to take a step back and discuss what these findings mean for patients and clinicians.